Tumor suppressor CHK2: Regulator of DNA damage response and mediator of chromosomal stability

Clinical Cancer Research

Volumn 17, Issue 3, 2011, Pages 401-405

  Stolz, Ailine ^a,b   Ertych, Norman ^a   Bastians, Holger ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; AZD 7762; BRCA1 PROTEIN; CAMPTOTHECIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; DEBROMOHYMENIALDISINE; DOXORUBICIN; EPOTHILONE DERIVATIVE; EXEL 9844; KU 0058684; KU 0058948; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NSC 109555; PF 447736; REGULATOR PROTEIN; SMALL INTERFERING RNA; TAXANE DERIVATIVE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VINCA ALKALOID; VRX 0466617; XL 844;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHROMOSOMAL INSTABILITY; COLON CARCINOMA; DNA DAMAGE; DNA REPAIR; DRUG POTENTIATION; DRUG TARGETING; ENZYME PHOSPHORYLATION; HUMAN; MITOSIS; MITOSIS SPINDLE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CHROMOSOMAL INSTABILITY; DNA DAMAGE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 79551698938     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1215     Document Type: Article

References (55)

1. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432:316-23. (Pubitemid 39551659)
2. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003;3:421-9. (Pubitemid 38340288)
3. Antoni L, Sodha N, Collins I, Garrett MD. CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?Nat Rev Cancer 2007;7:925-36.
4. Ahn J, Urist M, Prives C. The Chk2 protein kinase. DNA Repair (Amst) 2004;3:1039-47. (Pubitemid 38997946)
5. Blasina A, de Weyer IV, Laus MC, et al. A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase. Curr Biol 1999;9:1-10. (Pubitemid 29045789)
6. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J. The ATMChk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001;410:842-7. (Pubitemid 32303786)
7. Takai H, Naka K, Okada Y, et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J 2002; 21:5195-205.
8. Jallepalli PV, Lengauer C, Vogelstein B, Bunz F. The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J Biol Chem 2003;278:20475-9. (Pubitemid 36806343)
9. Jin J, Ang XL, Ye X, Livingstone M, Harper JW. Differential roles for checkpoint kinases in DNA damage-dependent degradation of the Cdc25A protein phosphatase. J Biol Chem 2008;283:19322-8.
10. Chehab NH, Malikzay A, Appel M, Halazonetis TD. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 2000;14:278-88.
11. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 2000; 14:289-300. (Pubitemid 30106484)
12. Jack MT, Woo RA, Hirao A, et al. Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc Natl Acad Sci USA 2002;99:9825-9. (Pubitemid 34831132)
13. Ahn J, Urist M, Prives C. Questioning the role of checkpoint kinase 2 in the p53 DNA damage response. J Biol Chem 2003;278:20480-9. (Pubitemid 36806344)
14. Lee JS, Collins KM, Brown AL, Lee CH, Chung JH. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 2000;404:201-4. (Pubitemid 30154490)
15. Zhang J, Willers H, Feng Z, et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 2004;24:708-18. (Pubitemid 38057922)
16. Zhuang J, Zhang J, Willers H, et al. Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining. Cancer Res 2006;66:1401-8. (Pubitemid 43259920)
17. Chen PL, Chen CF, Chen Y, et al. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci USA 1998;95:5287-92. (Pubitemid 28208590)
18. Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997;88:265-75. (Pubitemid 28015875)
19. Xia F, Taghian DG, DeFrank JS, et al. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc Natl Acad Sci USA 2001;98:8644-9. (Pubitemid 32678081)
20. Wang Q, Zhang H, Guerrette S, et al. Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1. Oncogene 2001;20:4640-9. (Pubitemid 32762436)
21. Brown KD, Rathi A, Kamath R, et al. The mismatch repair system is required for S-phase checkpoint activation. Nat Genet 2003;33:80-4. (Pubitemid 36068687)
22. Stevens C, Smith L, La Thangue NB. Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol 2003;5:401-9. (Pubitemid 36592262)
23. Yang S, Kuo C, Bisi JE, Kim MK. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol 2002;4:865-70. (Pubitemid 35331361)
24. Stolz A, Ertych N, Kienitz A, et al. The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells. Nat Cell Biol 2010;12:492-9.
25. Holland AJ, Cleveland DW. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol 2009;10:478-87.
26. Kais Z, Parvin JD. Regulation of centrosomes by the BRCA1-dependent ubiquitin ligase. Cancer Biol Ther 2008;7:1540-3.
27. Joukov V, Groen AC, Prokhorova T, et al. The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell 2006;127:539-52. (Pubitemid 44647427)
28. Perona R, Moncho-Amor V, Machado-Pinilla R, Belda-Iniesta C, Sanchez Perez I. Role of CHK2 in cancer development. Clin Transl Oncol 2008;10:538-42.
29. Ingvarsson S, Sigbjornsdottir BI, Huiping C, et al. Mutation analysis of the CHK2 gene in breast carcinoma and other cancers. Breast Cancer Res 2002;4:R4.
30. Oldenburg RA, Kroeze-Jansema K, Kraan J, et al. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res 2003;63:8153-7. (Pubitemid 37549462)
31. Williams LH, Choong D, Johnson SA, Campbell IG. Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Clin Cancer Res 2006;12:6967-72. (Pubitemid 44974490)
32. Zhang P, Wang J, Gao W, et al. CHK2 kinase expression is downregulated due to promoter methylation in non-small cell lung cancer. Mol Cancer 2004;3:14.
33. Meijers-Heijboer H, Van Den Ouweland A, Klijn J, et al. Lowpenetrance susceptibility to breast cancer due to CHEK2(*) 1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-9.
34. Seppala EH, Ikonen T, Autio V, et al. Germ-line alterations in MSR1 gene and prostate cancer risk. Clin Cancer Res 2003;9:5252-6. (Pubitemid 37413576)
35. Varley J, Haber DA. Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk. Breast Cancer Res 2003;5:123-5. (Pubitemid 36519403)
36. Cybulski C, Gorski B, Huzarski T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004;75:1131-5. (Pubitemid 39532081)
37. Szymanska-Pasternak J, Szymanska A, Medrek K, et al. CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors. Gynecol Oncol 2006;102:429-31. (Pubitemid 44353662)
38. Kilpivaara O, Alhopuro P, Vahteristo P, Aaltonen LA, Nevanlinna H. CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet 2006;43:e34.
39. Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999;286:2528-31.
40. Sodha N, Williams R, Mangion J, et al. Screening hCHK2 for mutations. Science 2000;289:359.
41. Falck J, Lukas C, Protopopova M, et al. Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway. Oncogene 2001;20:5503-10. (Pubitemid 32889487)
42. Sullivan A, Yuille M, Repellin C, et al. Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene 2002;21:1316-24. (Pubitemid 34214497)
43. Ricke RM, van Ree JH, van Deursen JM. Whole chromosome instability and cancer: a complex relationship. Trends Genet 2008;24:457-66.
44. Yu Q, Rose JH, Zhang H, Pommier Y. Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Lett 2001;505:7-12. (Pubitemid 32831020)
45. Ghosh JC, Dohi T, Raskett CM, Kowalik TF, Altieri DC. Activated checkpoint kinase 2 provides a survival signal for tumor cells. Cancer Res 2006;66:11576-9. (Pubitemid 46094165)
46. Carlessi L, Buscemi G, Larson G, et al. Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther 2007;6:935-44. (Pubitemid 46554563)
47. Jobson AG, Cardellina JH 2nd, Scudiero D, et al. Identification of a Bis-guanylhydrazone [4,40-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase. Mol Pharmacol 2007;72:876-84.
48. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004;3:513-9.
49. Matthews DJ, Yakes FM, Chen J, et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 2007;6:104-10. (Pubitemid 46173886)
50. Bunch RT, Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 1996;2:791-7. (Pubitemid 26168931)
51. Vogel C, Hager C, Bastians H. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res 2007;67:339-45. (Pubitemid 46142793)
52. Pires IM, Ward TH, Dive C. Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors. Br J Pharmacol 2010;159:1326-38.
53. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21. (Pubitemid 40559006)
54. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADPribose) polymerase inhibition. Cancer Res 2006;66:8109-15. (Pubitemid 44299177)
55. Kaestner P, Bastians H. Mitotic drug targets. J Cell Biochem 2010;111:258-65.